Compare AstraZeneca plc (AZN) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Rigetti Computing Inc — how do they compare? AstraZeneca plc trades at $168.76 (market cap $253.13B), while Rigetti Computing Inc trades at $15.08 (market cap $5.35B). The key difference: AstraZeneca plc is far larger — about 47.3× Rigetti Computing Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| AZN | RGTI | |
|---|---|---|
Market Cap | $253.13B | $5.35B |
Sector | Health | Technology |
52-Week High | $209.48 | $56.34 |
52-Week Low | $137.44 | $12.72 |
Enterprise Value | $279.37B | $4.94B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Rigetti Computing (RGTI) trades at $15.36, down 7.13% in the last 24 hours, with a bearish technical signal but bullish oscillators. The company reported a net loss of $216.21 million in 2025, with a negative net income margin of -2,253.59%, while revenue grew to $7.09 million. Recent news highlights quantum computing interest following Quantinuum's IPO and Rigetti's infrastructure developments, including the Fab-1 facility and a 108-qubit contract.
Despite significant losses and cash burn, analyst consensus is strongly bullish with an 85.71% buy rating and a $32.67 price target, suggesting over 112% upside. Key risks include high cash burn rates, intense competition, and the long timeline to quantum advantage, requiring careful risk assessment for speculative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
